Table 1.
Ex Vivo Challenge Assay Methods for Rectal (R1–R8), Cervical (C1–C4), and Vaginal (V1–V5) Data Sets: Treatments, Kits, and p24 Testing Days
| Data set | No. of ex vivo samplesa(donors) | Treatment(s) | p24 Kit | p24 Testing days (% missing) |
|---|---|---|---|---|
| R1 | 56 (24) | Baseline, placebo | National Cancer Instituteb | 1 (93), 4 (86), 7 (34), 11 (4), 14 (0) |
| R2 | 112 (48) | Baseline, placebo | National Cancer Institute | 1 (54), 4 (54), 7 (6), 11 (1), 14 (0) |
| R3 | 9 (3) | Baseline | National Cancer Institute | 4 (100), 7 (44), 11 (0), 14 (0) |
| R4 | 30 (10) | Baseline | National Cancer Institute | 4 (90), 7 (40), 11 (10), 14 (0) |
| R5 | 127 (32) | Baseline | Alliancec | 3 (89), 7 (52), 14 (24) |
| R6 | 14 (4) | Baseline | ZeptoMetrixd | 3 (0), 7 (0), 11 (0), 15 (0) |
| R7 | 144 (24) | Placebo | National Cancer Institute | 1 (99), 4 (97), 7 (51), 11 (13), 14 (6) |
| R8 | 10 (5) | Baseline | National Cancer Institute | 4 (40), 7 (0), 10 (0), 14 (0) |
| C1 | 28 (28) | Baseline | Alliance | 4 (0), 7 (0), 11 (0), 14 (0), 17 (0), 21 (0) |
| C2 | 30 (30) | Placebo | AlphaLISAb | 4 (0), 7 (0), 11 (0), 14 (0), 17 (0), 21 (0) |
| C3 | 24 (24) | Baseline | Alliance | 3 (0), 7 (0), 10 (0), 14 (0) |
| C4 | 6 (6) | Placebo | Alliance | 4 (0), 7 (0), 11 (0), 14 (0), 17 (0), 21 (0) |
| V1 | 29 (28) | Baseline | Alliance | 4 (0), 7 (0), 11 (0), 14 (0), 17 (0), 21 (0) |
| V2 | 30 (30) | Placebo | AlphaLISA | 4 (0), 7 (0), 11 (0), 14 (0), 17 (0), 21 (0) |
| V3 | 24 (24) | Baseline | Alliance | 3 (0), 7 (0), 10 (0), 14 (0) |
| V4 | 19 (19) | Baseline | Alliance | 7 (0), 14 (0), 21 (0) |
| V5 | 8 (2) | Baseline | ZeptoMetrix | 3 (0), 7 (0), 11 (0), 15 (0) |
All cultures were nonpolarized. Tissue setup within 1 h with the exception of V4, which was on ice overnight.
a
700 total tissue samples.
b
Frederick National Laboratory for Cancer Research, Frederick, MD.
c
Perkin Elmer, Waltham, MA.
d
Zeptometrix, Buffalo, NY.